Golotimod
- Generic Name
- Golotimod
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5
- CAS Number
- 229305-39-9
- Unique Ingredient Identifier
- 637C487Y09
- Background
SCV-07 (g -D-glutamyl-L-tryptophan) is a novel synthetic dipeptide that acts broadly on the Toll-like receptor pathway. It has been shown to stimulate T-lymphocyte differentiation, macrocytic phagocytosis, and specific immune responses, and enhance IL-2 and INF-g production. Due to this preferential activation of Th1 cytokine production, SCV-07 may show utility in treatment of tuberculosis. It can be administered orally or subcutaneously. In independent studies, treatment of tuberculosis with SCV-07 improved clearance of mycobacteria, improved cavity healing, improvements in immune parameters and reduced symptoms (fever, weakness, sweating, dry cough, productive cough, dyspnea, chest pain, tachycardia) without any adverse local or general effects. SCV-07 has shown efficacy in treating various viral and bacterial infections.
- Indication
Investigated for use/treatment in hepatitis (viral, C), infectious and parasitic disease (unspecified), and tuberculosis.
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
- First Posted Date
- 2011-03-08
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- SciClone Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT01310205
- Locations
- ๐บ๐ธ
Univ of Louisville Med/Dental Complex, Louisville, Kentucky, United States
๐บ๐ธWalter Reed Army Medical Center, Washington, Washington, United States
๐บ๐ธAGMG Clinical Research, Anaheim, California, United States
Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- SciClone Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT01247246
- Locations
- ๐บ๐ธ
The University of Illinois at Chicago, Chicago, Illinois, United States
๐บ๐ธDisney Family Cancer Center, Burbank, California, United States
๐บ๐ธArizona Oncology Services Foundation, Phoenix, Arizona, United States
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- SciClone Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00968357
- Locations
- ๐บ๐ธ
Arapahoe Gastroenterology, Littleton, Colorado, United States
๐บ๐ธA Professional Corporation, Palm Springs, California, United States
๐บ๐ธUniversity of Louisville, Louisville, Kentucky, United States
Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- SciClone Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT00756951
- Locations
- ๐บ๐ธ
Washington University in St Louis, St Louis, Missouri, United States
๐บ๐ธKarmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธJames Graham Brown Cancer Center, Lousiville, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.